<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805023</url>
  </required_header>
  <id_info>
    <org_study_id>BioGenCell Ltd</org_study_id>
    <nct_id>NCT02805023</nct_id>
  </id_info>
  <brief_title>Assessing the Feasibility of BGC101 in the Treatment of PAD &amp; CLI</brief_title>
  <acronym>EnEPC-CLI</acronym>
  <official_title>Phase 1/2, Open Label &amp; Double Blind Randomized Placebo Controlled Study to Assess the Safety and Efficacy of BGC101 (EnEPC) in the Treatment of PAD With CLI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGenCell Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laniado Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioGenCell Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells&#xD;
      enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic&#xD;
      stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral&#xD;
      arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal&#xD;
      pharmacological treatment or control of risk factors and/or had a revascularization failure,&#xD;
      and do not have the option of further revascularization treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BGC101 is designed to treat peripheral vascular disease in patients suffering from Critical&#xD;
      Leg Ischemia (CLI) also referred to as chronic limb threatening ischemia (CLTI).&#xD;
&#xD;
      This part of the study is designed as a placebo double-blind randomized controlled trial&#xD;
      (CRT) assessing the safety and efficacy of BGC101 in 45 eligible subjects in 2 Arms: Arm A:&#xD;
      BGC101 treatment and Arm B: Placebo treatment. The Arm A:Arm B ratio is 2:1 A single dose&#xD;
      treatment of the personalized cells by intramuscular injections into the affected leg takes&#xD;
      less than 10 minutes.&#xD;
&#xD;
      Cells from a standard blood draw (with no pre-treatment, bone marrow aspiration, mobilization&#xD;
      or apheresis) are transformed, within a day, into the investigational medicinal product&#xD;
      BGC101.&#xD;
&#xD;
      BGC101, intended for autologous use, is a 'ready-to-use' cell suspension in prefilled&#xD;
      syringes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Evaluation of adverse events - lack of severe adverse events)</measure>
    <time_frame>Six months</time_frame>
    <description>Evaluation of adverse events - lack of severe adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection of control medium only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGC101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of BGC101 (autologous EnEPC preparation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BGC101 (autologous EnEPC preparation)</intervention_name>
    <description>Intramuscular injections - single treatment session</description>
    <arm_group_label>BGC101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control medium</intervention_name>
    <description>Intramuscular injections - single treatment session</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have the time and ability to complete the study and comply with instructions.&#xD;
&#xD;
          2. Capable of understanding the purpose of the study and the contents of the informed&#xD;
             consent form&#xD;
&#xD;
          3. Age &gt; 18 Male or non-pregnant, non-lactating female&#xD;
&#xD;
          4. At least one of the clinical diagnostic indications of CLI:&#xD;
&#xD;
               -  Clinical assessment as Rutherford 4-5&#xD;
&#xD;
               -  Rest pain&#xD;
&#xD;
               -  Non-healing ischemic ulcers&#xD;
&#xD;
               -  Minor tissue loss&#xD;
&#xD;
          5. At least one of the hemodynamic indicators of severe peripheral arterial occlusive&#xD;
             disease:&#xD;
&#xD;
               -  Ankle brachial index (ABI) &lt;0.45&#xD;
&#xD;
               -  Toe brachial index (TBI) &lt;0.4&#xD;
&#xD;
               -  TcPO2 &lt; 40mmHg&#xD;
&#xD;
               -  A poor candidate for standard revascularization treatment options for peripheral&#xD;
                  arterial disease due to (1) unfavorable anatomy (e.g. small vessel disease with&#xD;
                  no major vessel stenosis/obstruction) OR (2) continued presence of smaller vessel&#xD;
                  microvasculature) disease six weeks or more after revascularization (performed as&#xD;
                  part of standard care) based on patency of the treated vessel(s).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following criteria are not eligible for this study.&#xD;
&#xD;
          1. Concurrent therapy that, in the Investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study medication.&#xD;
&#xD;
          2. Treatment with any investigational product within the last 6 months or enrollment in&#xD;
             any active study involving the use of investigational devices or drugs.&#xD;
&#xD;
          3. Presence of any other condition or circumstance that, in the judgment of the&#xD;
             investigator, might increase the risk to the patient or decrease the chance of&#xD;
             obtaining satisfactory data to achieve the objectives of the study.&#xD;
&#xD;
          4. Based on clinician opinion - prognosis of a major amputation (below or above the knee)&#xD;
             within 4 weeks from the assessment visit&#xD;
&#xD;
          5. Lack of femoral artery blood flow&#xD;
&#xD;
          6. Based on clinician opinion inability to perform intramuscular injections in cases such&#xD;
             as sever skin lesions, severe edema or morbid obesity&#xD;
&#xD;
          7. Blood transfusions during preceding 4 weeks (to exclude the potential of&#xD;
             non-autologous cells in the harvested blood)&#xD;
&#xD;
          8. Heart failure (NYHA 3-4)&#xD;
&#xD;
          9. Hgb Less than 9gm&#xD;
&#xD;
         10. Myocardial infarction, brain infarction, uncontrolled myocardial ischemia or&#xD;
             persistent severe heart failure (EF&lt; 25 %) during the preceding 3 months&#xD;
&#xD;
         11. Significant valvular disease or after valve replacement (based on medical record)&#xD;
&#xD;
         12. Renal failure (eGFR &lt;30, Chronic Kidney Damage Stage 4-5)&#xD;
&#xD;
         13. Liver function tests are more than three times normal upper limit (AST, ALT, ALP, GGT,&#xD;
             LDH).&#xD;
&#xD;
         14. Abnormal coagulation tests (PT(INR) &gt;2)&#xD;
&#xD;
         15. Pregnant or lactating women at entry to study&#xD;
&#xD;
         16. People who are unwilling to agree to use acceptable methods of contraception such as&#xD;
             condom from screening during the study to prevent pregnancy and chronic infectious&#xD;
             diseases (such as HIV-1,HIV-2, HBV, HCV)&#xD;
&#xD;
         17. Malignancy within the preceding 3 years, except for BCC&#xD;
&#xD;
         18. Concurrent acute infectious disease with septicemia&#xD;
&#xD;
         19. Chronic infectious diseases (HIV-1,HIV-2, Hepatitis viruses B and C)&#xD;
&#xD;
         20. Immunodeficiency syndrome&#xD;
&#xD;
         21. Cytotoxic drugs treatment&#xD;
&#xD;
         22. Inability to communicate (that may interfere with the clinical evaluation of the&#xD;
             patient)&#xD;
&#xD;
         23. Patient unlikely to be available for follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shlomo J Baytner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Vascular Surgery, Laniado Hospital, IL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Conte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of San Francisco - Division Vascular and Endovascular surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laniado Hospital</name>
      <address>
        <city>Netanya</city>
        <zip>42150</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Porat Y, Assa-Kunik E, Belkin M, Krakovsky M, Lamensdorf I, Duvdevani R, Sivak G, Niven MJ, Bulvik S. A novel potential therapy for vascular diseases: blood-derived stem/progenitor cells specifically activated by dendritic cells. Diabetes Metab Res Rev. 2014 Oct;30(7):623-34. doi: 10.1002/dmrr.2543.</citation>
    <PMID>24638886</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

